Indicator, Reagent, or Diagnostic Aid

Biogen Pledges $2 Billion Manufacturing Investment in North Carolina

4 days ago talkbio0Tagged Antisense Oligonucleotides, Aortic Valve Insufficiency, Automation, Biogen, Biotechnology, expansion, gene therapy, Investments, Manufacturing, North Carolina, Research Triangle Park

Biogen; manufacturing investment; North Carolina; Research Triangle Park; biotechnology; antisense oligonucleotides; gene therapy; automation; AI; expansion

NUCLIDIUM Sees Copper Isotopes as Future of Radiopharmaceuticals, Raises CHF 79M to Advance Clinical Development

2 weeks ago talkbio0Tagged cancer diagnostics, cancer therapeutics, copper isotopes, Malignant neoplasm of breast, Metastatic Prostate Carcinoma, Neoplasms, Neuroendocrine Tumors, NUCLIDIUM, NuriPro, Radiopharmaceuticals, Series B financing, Theranostics, TraceNET

NUCLIDIUM; copper isotopes; radiopharmaceuticals; Series B financing; Cu-NuriPro; NuriPro; TraceNET; oncology; theranostics; metastatic prostate cancer; neuroendocrine tumors; breast cancer; cancer diagnostics; cancer therapeutics

ITM Reports Positive Phase 3 Data for Radiopharmaceutical ITM-11 in Neuroendocrine Tumors, Challenging Novartis’ Lutathera

5 months ago talkbio0Tagged ITM-11, Lutathera, Neoplasms, Neurosecretory Systems, Novartis, Phase 3 COMPETE trial, Radiopharmaceuticals

ITM-11, radiopharmaceutical, Phase 3 COMPETE trial, neuroendocrine tumors, Lutathera, Novartis

Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects

5 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Capsid, Cu-Zn Superoxide Dismutase, Drug Development, Effect, gene therapy, off-target, payload, Preclinical, RNA, Small Interfering, Tracer, VY9323

SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay

Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships

5 months ago talkbio0Tagged AdvanCell, alpha therapies, cardiometabolic diseases, cellular targeting, Eli, Eli Lilly, MASH, OliX, Radiopharmaceuticals, strategic collaborations

Eli Lilly, AdvanCell, OliX Pharmaceuticals, targeted alpha therapies, radiopharmaceuticals, MASH, cardiometabolic diseases, strategic collaborations

Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies

5 months ago talkbio0Tagged AdvanCell, alpha therapies, Cancer Therapeutic Procedure, cardiometabolic diseases, cellular targeting, Eli, Eli Lilly, Interferes with, MASH, OliX, Radiopharmaceuticals, RNA

Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment